) is an evolutionary conserved RNA-processing enzyme with expanding roles in regulating cellular physiology. hPNPase old-35 was cloned using an innovative 'overlapping pathway screening' strategy designed to identify genes coordinately regulated during the processes of cellular differentiation and senescence. Although hPNPase old-35 structurally and biochemically resembles PNPase of other species, overexpression and inhibition studies reveal that hPNPase old-35 has evolved to serve more specialized and diversified functions in humans. Targeting specific mRNA or non-coding small microRNA, hPNPase old-35 modulates gene expression that in turn has a pivotal role in regulating normal physiological and pathological processes. In these contexts, targeted overexpression of hPNPase old-35 represents a novel strategy to selectively downregulate RNA expression and consequently intervene in a variety of pathophysiological conditions.
Human polynucleotide phosphorylase (hPNPase old-35 ) is an evolutionary conserved RNA-processing enzyme with expanding roles in regulating cellular physiology. hPNPase old-35 was cloned using an innovative 'overlapping pathway screening' strategy designed to identify genes coordinately regulated during the processes of cellular differentiation and senescence. Although hPNPase old-35 structurally and biochemically resembles PNPase of other species, overexpression and inhibition studies reveal that hPNPase old-35 has evolved to serve more specialized and diversified functions in humans. Targeting specific mRNA or non-coding small microRNA, hPNPase old-35 modulates gene expression that in turn has a pivotal role in regulating normal physiological and pathological processes. In these contexts, targeted overexpression of hPNPase Introduction RNA degradation and/turnover are major processes controlling RNA levels and are important regulators of physiological and pathological processes (Parker and Song, 2004) . Labile messenger RNAs to more stable non-coding RNAs (mostly ribosomal RNA and transfer RNA, but also the expanding class of small regulatory RNAs) are eventually degraded by a complex process involving the simultaneous or sequential interplay of multiple proteins. Many of these proteins are evolutionary conserved extending from prokaryotes to higher mammals and serving comparable functions. In eukaryotic cells, a variety of ribonucleases(RNases) act cooperatively, initially shortening the 3 0 poly (A) tail of an mRNA by deadenylases followed by the removal of the 5 0 cap structure by a decapping enzyme, which enables the degradation of the transcript by a 5 0 -3 0 exoribonuclease. Alternatively, the mRNA might be degraded from the 3 0 end by the cytoplasmic exosome, a multiprotein complex of diverse 3 0 -5 0 exoribonucleases. Polynucleotide phosphorylase (PNPase) is a 3 0 -5 0 exoribonuclease that uses the phosphorolytic mechanism to degrade RNA (Mohanty and Kushner, 2000; Yehudai-Resheff et al., 2001; . It is conserved evolutionarily and is expressed in different species including bacteria, plants, worms, flies, mice and humans. Our group cloned the human homolog of polynucleotide phosphorylase (hPNPase old-35 ) in the unique contexts of differentiation and senescence, using an 'overlapping pathway screening' scheme. We documented that hPNPase old-35 has a key role in regulating both of these fundamental physiological processes (Leszczyniecka et al., 2002 (Leszczyniecka et al., , 2004 Sarkar et al., 2003 Sarkar et al., , 2004 Sarkar et al., , 2005 Sarkar et al., , 2007 . We presently review recent advances in our understanding of hPNPase old-35 -mediated RNA degradation, in particular its ability to target different classes of RNAs.
Cloning, expression and localization of hPNPase old-35 hPNPase old-35 was cloned by using an overlapping pathway screening approach (Leszczyniecka et al., 2002) during a screen for genes upregulated in the process of terminal cellular differentiation and senescence. Although terminal cell differentiation and cellular senescence represent two discrete phenomena, these processes have several common characteristics. Both are distinguished by irreversible growth arrest associated with marked inhibition of DNA synthesis, inhibition of telomerase activity and modulation of discrete programs of gene expression, especially upregulation of cyclindependent kinase inhibitors (Fisher et al., , 1986 Campisi, 1992) . Combined treatment of metastatic human melanoma cells HO-1 with recombinant human fibroblast interferon (IFN)-b and the protein kinase C activator mezerein induces irreversible growth arrest accompanied by morphological, biochemical, antigenic and gene expression changes culminating in a state of 'terminal differentiation (Fisher and Grant, 1985; Fisher et al., , 1986 Guarini et al., 1989 Guarini et al., , 1992 Jiang et al., 1993 Jiang et al., , 1995 . Screening of a temporal complementary DNA library generated from terminally differentiated HO-1 melanoma cells with complementary DNAs from senescent progeriod fibroblasts identified 75 genes, termed old-1 to -75, which were upregulated during both terminal differentiation and senescence. Sequence analysis of one particular clone, old-35, confirmed its identity to the PNPase gene, resulting in the gene being renamed hPNPase old-35 (Leszczyniecka et al., 2002) . The hPNPase old-35 gene consists of 28 exons and 27 introns spanning 54 kb in chromosome 2p15-2p16.1 . Of interest, this unstable genomic region is prone to cytogenetic alterations in human cancers and in various genetic disorders (Kirschner et al., 1999) such as B-cell lymphoma (Fukuhara et al., 2006) , type I hereditary nonpolyposis colorectal cancer, familial male precocious puberty, Carney complex, Doyne's honeycomb retinal dystrophy and DYX-3, a form of familial dyslexia (Kirschner et al., 1999) . hPNPase old-35 mRNA expression could be detected in all normal tissues analyzed with the highest expression being detected in heart and brain (Leszczyniecka et al., 2002) . However, to date, there is no evidence linking expression and function of hPNPase to any of the aforementioned pathological processes.
In bacteria, PNPase autogenously regulates its expression by promoting the decay of PNPase mRNA by binding to the 5 0 -untranslated leader region of an RNase III-processed form of this transcript (Jarrige et al., 2001) . To date the only known regulators of hPNPase old-35 transcription are type I IFN (IFN-a and IFN-b) in both normal and cancer cells with diverse backgrounds irrespective of their p53 and Rb status (Leszczyniecka et al., 2002) . Double-stranded RNA and poly(I) poly(C), a known inducer of IFN-a and IFN-b, also stimulate hPNPase old-35 expression while IFN-g and tumor necrosis factor-a have minimal or no effect, respectively. hPNPase old-35 is an early IFN response gene and its induction depends on the Janus-activated kinase/ signal transducers and activators of transcription signal transduction pathways. Analysis of the hPNPase old-35 promoter identified an IFN-stimulated response element that showed increased binding of ISGF3 complex on IFN-b treatment . Mutation in this site abolished IFN-b induction of the promoter indicating that hPNPase old-35 is regulated at the level of transcription. In addition to the IFN-stimulated response element, the hPNPase old-35 promoter contains additional putative regulatory protein-binding sites, including a site for E2F transcription factor 3 (E2F3), a transcriptional repressor that is responsible for gene silencing during the G 1 to S phase transition (Gewartowski et al., 2006) . Studies using cellular fractionation and/or immunofluorescence showed that endogenous hPNPase old-35 and overexpressed C-terminal myc-tagged hPNPase old-35 localize only to the mitochondria (Piwowarski et al., 2003; Chen et al., 2006) . hPNPase old-35 has a typical mitochondrial localization signal at the NH 2 -terminal and it is imported into the mitochondria by i-AAA (ATPases associated with several diverse cellular activities) protease Yme1, localized into mitochondrial intermembrane space and maintains mitochondrial homeostasis (Chen et al., 2006) . However, our studies document that overexpressed C-terminal HA-tagged hPNPase old-35 localizes both in cytosol and mitochondria (Sarkar et al., 2005) indicating that hPNPase old-35 might reside within or outside mitochondria. In these contexts, the targets and the consequences of hPNPase old-35 expression in different cellular compartments may be distinct and diverse, thereby expanding the repertoire of activities of this interesting enzyme.
RNA degradation machinery: PNPase and exosome
RNases are enzymes that are master regulators of stability and decay of RNA (Deutscher, 1993a, b; Allmang et al., 1999; Deutscher and Li, 2001 ). Depending on their degradative properties, RNases are divided into two functional classes, endoribonucleases that cleave RNA molecules internally and exoribonucleases that act at the end of RNA chains (Deutscher, 1993b) . RNA decay pathways in two of the most comprehensively studied model systems, the prokaroyte Escherichia coli and the eukaryote Saccharomyces cerevisiae, are different. In eukaryotes exoribonucleases can degrade RNA both at 5 0 -3 0 and 3 0 -5 0 directions (Deutscher and Li, 2001) , whereas in prokaryotes RNA degradation takes place only in the 3 0 -5 0 direction. However, an interesting aspect of RNA decay in both prokaryotes and eukaryotes is the presence of multiprotein complexes known as the degradosome and the exosome, respectively.
In E. coli, PNPase is associated with the endonuclease RNase E, RNA helicase and the glycolytic enzyme enolase to form the degradosome and executes its processive 3 0 -5 0 phosphorolysis or degradation of RNA species on endonucleolytic cleavage by RNase E. PNPase acts as an integral component of degradosome like RNA-helicase and enolase. In contrast, in yeast, PNPase is absent and the exosome, a complex of multiple exoribonuclease performs RNA degradation in both the cytoplasm and the nucleus (Mitchell et al., 1997; Hoof and Parker, 1999; Raijmakers et al., 2004; Buttner et al., 2006) . However, PNPase has been identified in higher animals such as mouse, rat and human indicating that the exosome and PNPase might serve specialized functions in these species (Leszczyniecka et al., 2002 (Leszczyniecka et al., , 2004 Raijmakers et al., 2002) .
In all species, PNPase contains five motifs that are conspicuously preserved through evolution extending from prokaryotes and plants to mammals (Leszczyniecka et al., 2004; Almeida et al., 2008) . Two conserved catalytic RNase PH regions, a small domain of B250 a.a. residues related to the E. coli RNase PH enzyme and involved primarily in the 3 0 processing of transfer RNA precursors, are present at the N-terminus of hPNPase old-35 (Leszczyniecka et al., 2004) . These RNase PH domains are separated by an a-helix that is unique to PNPase (Symmons et al., 2002) . The RNA-binding property of hPNPase old-35 is conferred by two C-terminal RNAbinding domains, KH and S1 (Symmons et al., 2000; Raijmakers et al., 2002; Symmons et al., 2002; Leszczyniecka et al., 2002 Leszczyniecka et al., , 2004 . In addition to the characteristic five motifs, plant PNPase contains an N-terminal target peptide allowing translocation to chloroplast and the mammalian PNPase contains an N-terminal mitochondrial localization signal facilitating its subcellular localization in mitochondria (Piwowarski et al., 2003; Yehudai-Resheff et al., 2003 and Sarkar et al., 2005) . The catalytic activity of PNPase enzyme in bacteria is located mainly in the second RNase PH domain (Jarrige et al., 2002) while in spinach chloroplasts, both RNase PH domains have equal polyadenylation and exoribonuclease activity. Deletion and mutation analysis have identified the critical regions of bacterial PNPase activity. Deletion of the S1 or KH RNA-binding domain reduces the enzymatic activity by 50-or 19-fold, respectively, while deletion of both S1 and KH domains results in 1% of the enzymatic activity (Stickney et al., 2005) . These deletions do not interfere with interaction with RNase E to form the degradosome. Site-directed mutagenesis reveals that the catalytic center of PNPase is located in the second RNase PH domain around the binding site for tungstate, a phosphate analogue (Jarrige et al., 2002) . Interestingly, a G454D mutation in the second RNase PH domain displays defective RNA binding and impairs the autogenous regulation of PNPase mRNA indicating that in addition to S1 and KH domains, the catalytic domains are also capable of binding to RNA (Regonesi et al., 2004) .
The alignment of the proteins in eukaryotic exosome clearly points to a structural similarity with bacterial PNPase. The three-dimensional structure of the PNPase from the bacterium Streptomyces antibioticus has revealed that the enzyme is a ring (doughnut)-shape formed by a homotrimeric complex, with the hexameric PH-domains surrounding a central channel that can accommodate a single-stranded RNA molecule (Symmons et al., 2002) . Similarly, the same core structure is formed in the exosome: six RNase PH homologues comprise the core while three additional exosome subunits, which contain S1 RNA-binding domains, are positioned on the outer surface of the ring (Mitchell and Tollervey, 2000; Raijmakers et al., 2002; Symmons et al., 2002) .
Specialized functions of hPNPase old-35
: RNA degradation
In eukaryotes, the poly(A) tail of mRNA first becomes deadenylated by three different enzyme complexes, the first composed mainly of Ccr4p and Pop2p, the second containing Pan2p and Pan3p and the third is a poly(A)-specific exonuclease called PARN (poly(A) RNases) (Parker and Song, 2004) . Following deadenylation, a decapping enzyme consisting of Dcp1p and Dcp2p removes the 5 0 cap structure thus facilitating degradation by the 5 0 , 3 0 exoribonuclease Xrn1p (Tucker and Parker, 2000) . Alternatively, after deadenylation, mRNA can be degraded in a 3 0 -5 0 direction by the exosome complex and the oligonucleotide cap structure is hydrolyzed by the decapping enzyme DcpS (Wang and Kiledjian, 2001 ). In addition, mRNA can also be degraded by endoribonucleases and aberrant mRNA may be degraded by specialized pathways such as nonsense-mediated decay or nonstop decay that degrade mRNA containing a premature stop codon or lacking a stop codon, respectively (Dodson and Shapiro, 2002; Frischmeyer et al., 2002; Cao and Parker, 2003) .
PNPase, as a phopsphorylase, it incorporates Pi and adenosine diphosphate (ADP) in degradation and polymerization process, respectively (Littauer and Grunberg-Manago (1999) . Optimal degradation activity depends on the concentration of Pi and it varies from species to species (Portnoy et al., 2005) . The human PNPase is active in much lower concentration of Pi compared with bacterial PNPase (Portnoy et al., 2005) . The specificity of the enzyme for the polymerization reaction is, like that of the E. coli. PNPase, is high for ADP, with much less activity for other nucleotide diphosphates (NDPs) and no activity for ATP or other nucleotide triphosphates (NTPs). More interestingly, hPNPase displays no preferential activity for polyadenylated RNA-like bacterial or chloroplast PNPase (Portnoy et al., 2005) .
c-myc mRNA is the target of hPNPase old-35 In the cytoplasm, adenoviral-mediated overexpression of hPNPase old-35 could directly degrade c-myc mRNA by virtue of its 3 0 -5 0 exoribonuclease property and this degradation is specific for c-myc as compared with other mRNAs, such as c-jun, glyceraldehyde 3-phosphate dehydrogenase or GADD 34 . It is still not clear what confers the specificity of hPNPase old-35 for c-myc mRNA. There might be a specific sequence in c-myc mRNA that allows hPNPase old-35 binding and degradation. In E. coli, PNPase degrades a family of cold shock proteins that do not show any sequence similarity (Yamanaka and Inouye, 2001) . Considering this observation, the secondary structure of the mRNA rather than its primary sequence might be the determining factor for specificity of hPNPase old-35 binding and degradation of c-myc. The presence of either of the RNase PH domains was sufficient for degradation of c-myc mRNA and induction of morphological, biochemical and gene expression changes by hPNPase old-35 (Sarkar et al., 2005) (described in next section of this review). Although in bacteria, presence of the KH and the S1 RNA-binding domains are required for functional activity of PNPase, hPNPase old-35 still retained its functional activity on removal of KH and S1 domains (Sarkar et al., 2005; Stickney et al., 2005) .
hPNPase might be involved in degradation of RNA in mammalian mitochondria In mammals, mitochondrial RNA (mtRNA) degradation is not well defined as no RNA degrading complex has been identified. The current view is largely based on our understanding of the E. coli RNA degradosome and yeast mitochondrial exosome. Similar to cytoplasmic mRNAs, mtRNAs also require long poly (A) tails for recruitment of poly (A)-binding proteins for maintenance of stability (Temperley et al., 2003) . Human mitochondria-specific poly (A) polymerase has been shown to synthesize mtRNA poly(A) tails. Knocking down poly (A) polymerase by small interfering RNA decreases the length of poly (A) tail of mitochondrial mRNA and decreases their steady-state levels (Nagaike et al., 2005) . The mitochondrial membrane potential (Dc) and oxygen consumption also decreased in poly (A) polymerase small interfering RNA-treated cells. In contrast, knocking down of hPNPase showed significantly extended poly(A) tails of mtRNA although it did not affect the steady-state levels of these mRNAs or their translational products (Temperley et al., 2003; Nagaike et al., 2005) . In these studies, only the levels of full-length mtRNAs were quantified without considering the truncated and polyadenylated mtRNAs that normally occur in human mitochondria (Slomovic et al., 2005) . In normal mammalian mitochondria, truncated and polyadenylated transcripts do not accumulate and are rapidly degraded (See and Fitt, 1972) . Recent studies suggest that knocking down human suppressor of Var1 3 helicase leads to an accumulation of shortened polyadenylated mtRNA species (Khidr et al., 2008) . Human suppressor of Var1 3 makes a heteropentameric complex with hPNPase at a 2:3 molar ratio in a coordinated manner to degrade double-stranded RNA (dsRNA) substrates (Wang et al., 2009) . Considering this recent finding it is hypothesized that the human suppressor of Var1 3-hPNPase complex might be involved in removing truncated RNA species through hPNPase-mediated degradation. Further experimentation is required to validate this possibility.
Modulation of miRNAs by hPNPase old-35 MicroRNAs (miRNAs), a subset of non-coding RNAs, are 22-25-nt long endogenously initiated short RNA molecules that regulate gene expression at the posttranscriptional level and have important roles in a multiplicity of biological functions, including cell differentiation, tumorigenesis, apoptosis and metabolism (Ambros, 2004 ). An individual miRNA is able to control the expression of more than one target mRNA and each mRNA may be regulated by multiple miRNAs. The interaction between miRNA and mRNA are usually restricted to the 'seed'-6-8-nt at the 5 0 region of miRNA and partially complementary sites in the 3 0 UTRs of target mRNAs, resulting in either translational repression or target degradation (Kim, 2005) . miRNAs are initially transcribed principally by either RNA polymerase II or RNA polymerase III as long primary transcripts of miRNAs, which are further processed by the nuclear RNase Drosha and cytoplasmic RNase Dicer to produce precursor miRNAs and mature miRNAs, respectively (Calin and Croce, 2006) (Figure 1 ). In principle, miRNA abundance could be controlled by developmental and tissue specific signaling (Landgraf et al., 2007) . The steady-state levels Figure 1 Schematic model of miRNA biogenesis and stability. After synthesis by RNA polymerase II, primary transcripts of (pri) miRNA are recognized by Drosha, which excises the hairpin precursor and released precursor (pre) miRNA. From nucleus, exportin five delivers the miRNA precursor to Dicer and its RNA-binding partner in the cytoplasm for final processing to the mature 22-nt miRNAs. One strand is selected for stable association with Argonaute, in which it serves as a guide to target and regulate specific mRNAs. By executing exonuclease activity hPNPase old-35 specifically degrades mature miRNAs. However, their substrate recognition mechanism is unknown. of miRNAs, crucial for its profound impact on a wide array of biological processes (Tsuchiya et al., 2006; Filipowicz et al., 2008) are presumably regulated by the opposing activities of miRNA biogenesis and degradation.
In the biogenesis process, miRNAs might be regulated both transcriptionally and post-transcriptionally. Numerous Pol II-associated transcription factors such as myogenin and MYOD1 are involved in transcriptional control of miR-1 and miR-133 genes during myogenesis (Rao et al., 2006; Chen et al., 2006) . Some miRNAs are under the control of tumor suppressive p53 (reviewed by He et al., 2007) or the oncogenic transcription factor c-myc (He et al., 2005; Chang et al., 2008) . Epigenetic control also contributes to miRNA gene regulation (Bueno et al., 2008) . Several miRNAs expressions are also regulated at the post-transcriptional level. The primary transcript of let-7 (pri-let-7) is expressed in both undifferentiated and differentiated ES cells, whereas mature let-7 is detected only in differentiated cells, indicating that let-7a might be post-transcriptionally controlled (Suh et al., 2004; Thomson et al., 2006; Wulczyn et al., 2007) . Excluding this activity, turnover of miRNA also might contribute in maintaining its level; however, this remains a largely unexplored area. In Caenorhabditis elegans (Kennedy et al., 2004) an exoribonuclease ERI1 (also known as THEX1) was previously shown to degrade small interfering RNAs. Another exoribonuclease named small RNA degrading nuclease proteins were reported to affect the stability of miRNAs in plants (Ramachandran and Chen, 2008) . Very recently, we demonstrated a role of hPNPase old-35 in human miRNAs degradation (Das et al., 2010) . This novel way of regulating miRNA levels is being actively explored by our research group. hPNPase old-35 downregulates specific miRNAs. miRNA microarray analysis between Ad.hPNPase old-35 -and Ad.vec-infected human melanoma cells identified specific miRNAs differentially regulated by hPNPase old-35 , which have been subsequently validated by qPCR and Northern blot analyses. Of interest, robust downregulation of several miRNAs (for example, miR-221, miR-222 and miR-106b) by hPNPase old-35 was observed while a number of miRNAs were not affected (miR-184, miRlet7a) suggesting specificity and selectivity of this enzyme-mediated miRNA downregulation. Moreover, an inverse correlation between these miRNAs and hPNPase old-35 in primary melanocytes and different melanoma cell lines support the biological relevance of this protein in regulating specific miRNAs (Figure 2 ).
Post-transcriptional modification of miRNA biogenesis by hPNPase old-35 . miRNA genes are initially transcribed as long primary transcripts of miRNAs, which are further processed to produce precursor miRNAs and mature miRNAs (Figure 1 ) (Calin and Croce, 2008 , a pre-requisite step for enzymatic activity indicating that miRNAs undergo enzymatic degradation.
hPNPase old-35 preferentially degrades miR-221. Although the overexpression of hPNPase old-35 selectively downregulates specific miRNAs, the preferences to miRNAs varied significantly. In melanoma cells, degradation of miR-221 by hPNPase old-35 was more profound compared with other miRNAs tested. This preferential activity might be attributed to high binding affinity of hPNPase old-35 to the mature miR-221, a hypothesis that needs to be tested (Figure 3) . , which in turn raises the level of p27 Kip1 , a cyclin-dependent kinase inhibitor protein, by degrading c-myc mRNA . However, forced degradation of c-myc by small interfering RNA did not completely block IFN-b-mediated growth arrest indicating the existence of additional pathways potentially regulating this effect (Barnes and Karin, 1997; Obaya et al., 1999; O'Hagan et al., 2000) . As miR-221 directly targets p27
Kip1 mRNA (Fornari et al., 2008) , IFN-b-mediated hPNPase old-35 -dependent miR-221 downregulation might also be involved in inducing growth arrest.
Other biological functions of hPNPase old-35 protein hPNPase old-35 and cellular senescence Senescence is a state of irreversible growth arrest induced spontaneously in primary cells after a finite number of population doublings (replicative senescence) or induced by endogenous and exogenous acute and chronic stress signals (stress-or aberrant-signalinginduced senescence (Hayflick, 1976; Serrano et al., 1997) . hPNPase old-35 was first described as an induced gene during terminal differentiation and cellular senescence two end-stage processes sharing several overlapping features including irreversible growth arrest, marked inhibition of DNA synthesis and modulation of telomerase activity . Overexpression of full-length hPNPase old-35 or either one of its RNase PH domains in human melanoma cells and melanocytes induces distinctive changes associated with senescent phenotypes (Sarkar et al., , 2005 including induction of SA-b-gal activity, cell cycle arrest in G 1 phase with inhibition of DNA synthesis followed by induction of apoptosis, and inhibition of telomerase activity. In total, these findings indicate that hPNPase old-35 might have an essential role in senescence-and differentiationassociated growth inhibition. Mechanistically, hPNPase . The increase in p27 kip1 is most likely secondary to the decrease in c-myc that controls p27 kip1 expression by multiple mechanisms (Barnes and Karin, 1997; Obaya et al., 1999; O'Hagan et al., 2000) . However, it is also a consequence of downregulation of miR-221 that specifically targets the mRNA of p27 kip1 . As oxidative stress mediates cellular senescence (Colavitti and Finkel, 2005; Passos et al., 2006 ) the induction of reactive oxygen species (ROS) following upregulation of hPNPase old-35 could also be involved in induction of the senescent phenotype. Further studies are necessary to investigate the role of the interactive network of c-myc, miR-221, p27 kip1 and ROS in regulating the senescence process.
hPNPase old-35 and aging-associated inflammation Aging represents a conundrum in the evolution of higher organisms that is associated with progressive degenerative diseases the underlying pathology of which is often chronic inflammation (Kiecolt-Glaser et al., 2003) . Oxidative stress has an important role in induction of chronic inflammation. ROS generated by mitochondria induce oxidative stress in DNA, protein and lipid and this activity is more prominent in tissues Comparative degradation between miR-221, miR-222 and miR106b at a 2 h time point using in vitro degradation assays. P-value was calculated using Student's t-test by comparing the specific miRNA normalized by miR-RNU-44. The data represent mean ± s.d. of two independent experiments each done in triplicate. ) of 5000 vp/cells for 3 days and subjected to miRNA microarrays and potential target miRNAs miR-106b, miR-25, miR-221, miR-222, miR-let7a and miR-184 were validated for differential expression by using primary-and mature miRNA-specific Taqman probes with qPCR. (b) Northern blotting was performed to detect mature miRNAs and its precursor species by using specific probes. Expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), miR-RNU44 and U6 RNA were used to normalize the pri-and mature miRNA in qPCR and Northern blotting data, respectively. from aged individuals or aged experimental animals than their young counterparts (Harman, 1957; Hagen et al., 1997; Chen, 2000; Finkel and Holbrook, 2000) . A prominent mechanism by which ROS modulates diverse intracellular molecular processes is by turning on the expression of proinflammatory cytokines (Baldwin, 1996) and through regulating the activity of nuclear factor (NF)-kB (Schreck et al., 1992) . hPNPase old-35 is localized in mitochondria and induces ROS that subsequently leads to NF-kB activation, which is inhibited by anti-oxidant N-acetyl-L-cysteine. Activation of NF-kB leads to increased production of proinflammatory cytokines such as interleukin-6, interleukin-8, RANTES and matrix metalloproteinase-3 (MMP-3), which could also be inhibited by treatment with N-acetyl-L-cysteine suggesting the involvement of hPNPase old-35 in producing pathological changes associated with aging by generating pro-inflammatory cytokines via ROS and NF-kB (Sarkar et al., 2004; .
Overexpression of hPNPase old-35
-induced growth inhibition in different cancer cells and its molecular mechanism On the basis of cell line studies it is observed that slow and sustained overexpression of hPNPase old-35 induces growth arrest ultimately culminating in apoptosis, whereas rapid overexpression of hPNPase old-35 directly promotes apoptosis without cell cycle changes. These observations imply that inhibition of cell cycle progression and induction of apoptosis by hPNPase old-35 involves multiple intracellular targets and signaling pathways. In the context of cell cycle, hPNPase old-35 overexpression induces growth arrest at both G 1 /S and G 2 /M phase depending on the cell types, although the molecular mechanism is quite similar (Sarkar et al., 2004; Chan et al., 2008; Van Maerken et al., 2009) . In all cases, c-myc is downregulated by hPNPase old-35 accompanied with upregulation of cyclin-dependent kinase inhibitor, p21 CIP1/WAF-1/MDA-6 and p27 KIP1 that have essential roles in cell cycle arrest either in the G 1 or G 2 /M phase. Apoptosis-inducing activity of hPNPase old-35 is mediated by activation of double-stranded RNAdependent protein kinase (Sarkar et al., 2007) . Activation of RNA-dependent protein kinase by hPNPase old-35 precedes phosphorylation of eukaryotic initiation factor-2A and induction of growth arrest and DNA damageinducible gene 153 (GADD153) that culminates in the shutdown of protein synthesis and apoptosis. Activation of RNA-dependent protein kinase by hPNPase old-35 also nitiates downregulation of the anti-apoptotic protein Bcl-xL. All of these studies elucidate a novel pathway by which an evolutionary conserved RNA-metabolizing enzyme, hPNPase old-35 , regulates cell growth and viability.
Role of hPNPase old-35 in maintaining mitochondrial homeostasis On the basis of the localization in the mitochondrial intermembrane space, hPNPase old-35 is predicted to have a major role in mitochondrial bioenergetics. Evidence for maintaining homeostasis comes from both loss-offunction and gain-of-function studies, although contradictory results also indicate that knocking down hPNPase old-35 does not affect mitochondrial morphology or the rate of oxygen consumption (Nagaike et al., 2005) . Knocking down of hPNPase old-35 reduced mitochondrial DC and enzymatic activities of couple respiratory complexes compared with control cells resulting in mitochondrial dysfunction such as lactate accumulation and reduction of steady-state ATP levels (Chen et al., 2006a, b, c) . Concurrently, overexpression results in increased ROS accumulation over time confirming a role for hPNPase old-35 in mitochondrial homeostasis (Sarkar et al., 2004) . However, it is not understood how mitochondrial homeostasis is precisely regulated by hPNPase old-35 , as no known substrates are located in the intermembrane space. Accordingly, one must also consider potential non-enzymatic functions of hPNPase old-35 in maintenance of mitochondrial homeostasis. It is possible that hPNPase old-35 affects oxidative phosphorylation directly by impacting on components of the respiratory complexes or indirectly through interference in mitochondrial fusion. Consistent with this possibility, a very recent study (Wang et al., 2010) showed that components of the electron transport chains were reduced at both RNA and protein levels in PNPase RNA interference-transfected HEK293 cells as compared with controls. A similar result was also observed in liver mitochondria from a liver-specific PNPase knockout mouse model suggesting that the decrease in functional electron transport chain complexes was responsible for decreased respiration. Furthermore, the ultrastructure of liver mitochondria from liver-specific knockout mice displayed disordered circular and smooth inner membrane criste, similar to mitochondria having impaired components of oxidative phosphorylation pathways. Citrate synthase activity, routinely used as a marker of aerobic capacity, also decreased in the liver of PNPase knockout mice compared with the wild-type mice establishing a pivotal role of PNPase in mitochondrial morphogenesis and respiration in vivo. Additionally, a number of studies indicate that hPNPase old-35 potentially maintains highfidelity translation by sequestering oxidative stressdamaged RNA (Hayakawa and Sekiguchi, 2006; Wu and Li, 2008) supporting potential exoribonucleaseindependent activity of this enzyme in maintaining normal mitochondrial function.
Role of PNPase in translocation of RNA in mitochondria Although the molecular mechanism of mitochondrial import of nuclear-encoded proteins is well defined, little is known about the factors that control mitochondrial RNA import. Wang et al. (2010) have now demonstrated a direct involvement of PNPase in regulating specific cytosolic RNA import into the mitochondrial matrix. This function of PNPase is independent of its RNA-processing function, as inactivation of RNA processing by mutation did not affect RNA import. Mammalian RNase P localizes in mitochondria and functions in the processing of transfer RNAs during the maturation of mitochondrial transcripts (Chang and Clayton, 1987) . RNase P is encoded in the nucleus and PNPase is directly involved in translocation of this enzyme. However, the exact mechanism by which PNPase augments RNA import is not yet known. It is hypothesized that PNPase imports RNAs from the cytosol into the intermembrane space and then passes this RNA to another protein or complex that facilitates passage of the RNAs through the innermembrane into the matrix. Interestingly PNPase showed specificity toward import of cytosolic RNAs based on their secondary structure. Consistent with in vitro findings, mitochondrial RNA import was severely compromised in the liver mitochondria from liver-specific PNPase (pnpt1) knockout mice (Wang et al., 2010) .
Summary
The gradual unraveling of the multifaceted functions of hPNPase old-35 illustrates its prominent role in regulating diverse physiological and pathological processes ( Figure 4) . As hPNPase old-35 displays substrate specificity, either mRNA or miRNA, the elucidation of how it elicits such specificity will significantly improve our understanding of its RNA-processing functions. The preferential degradative effects on specific miRNAs might be applicable to selectively downregulate oncogenic miRNA in different malignancies and thus might be amenable for developing a novel potential anticancer therapy. miRNAs have recently been shown to be involved in developing drug resistance and thus combinatorial therapy of hPNPase old-35 and appropriate therapeutic drug might be an effective approach for combating cancer. The lack of expression in different cancer cells while the ubiquitious expression in multiple organ/tissues raises the relevant question whether hPNPase old-35 serves any specialized function in specific organs? Animal models with either conditional overexpression or knockdown of PNPase expression will be extremely valuable in answering these questions. Importantly, these models will facilitate studies on senescence and IFN action, including its anti-viral properties and role in inflammatory disease processes as well as maintaining mitochondrial homeostasis. Strategies using natural compounds and/or small molecules to block the enzymatic functions of hPNPase old-35 might provide effective therapeutic benefit for inflammation or even provide a means of retarding the aging process and enhancing longevity.
Overall, delineation of the nuances of how hPNPase old-35 induces its diverse effects in different organisms offers significant potential to comprehend the evolutionary relevance of this molecule and this will help delineate its quintessential role in both normal physiology and in disease pathology.
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